Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Radiother Oncol ; 119(2): 291-9, 2016 05.
Article in English | MEDLINE | ID: mdl-26874542

ABSTRACT

BACKGROUND AND PURPOSE: High arginase-1 (Arg) expression by myeloid-derived suppressor cells (MDSC) is known to inhibit antitumor T-cell responses through depletion of l-arginine. We have previously shown that nitric oxide (NO), an immune mediator produced from l-arginine, is a potent radiosensitizer of hypoxic tumor cells. This study therefore examines whether Arg(+) overexpressing MDSC may confer radioresistance through depleting the substrate for NO synthesis. MATERIAL AND METHODS: MDSC and Arg expression were studied in preclinical mouse CT26 and 4T1 tumor models and further validated in rectal cancer patients in comparison with healthy donors. The radioprotective effect of MDSC was analyzed in hypoxic tumor cells with regard to l-arginine depletion. RESULTS: In both mouse tumors and cancer patients, MDSC expansion was associated with Arg activation causing accelerated l-arginine consumption. l-Arginine depletion in turn profoundly suppressed the capacity of classically activated macrophages to synthesize NO resulting in impaired tumor cell radiosensitivity. In advanced cT3-4 rectal cancer, circulating neutrophils revealed Arg overexpression approaching that in MDSC, therefore mounting a protumor compartment wherein Arg(+) neutrophils increased from 17% to over 90%. CONCLUSIONS: Protumor Arg(+) MDSC reveal a unique ability to radioprotect tumor cells through l-arginine depletion, a common mechanism behind both T-cell and macrophage inhibition.


Subject(s)
Arginase/physiology , Arginine/metabolism , Myeloid-Derived Suppressor Cells/physiology , Rectal Neoplasms/radiotherapy , Animals , HCT116 Cells , Humans , Macrophages/physiology , Mice , Neutrophils/physiology , Nitric Oxide/biosynthesis , Rectal Neoplasms/metabolism , T-Lymphocytes/immunology
2.
Oncotarget ; 6(14): 12369-82, 2015 May 20.
Article in English | MEDLINE | ID: mdl-25869209

ABSTRACT

Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of cells that accumulate in tumor-bearing subjects and which strongly inhibit anti-cancer immune responses. To study the biology of MDSC in colorectal cancer (CRC), we cultured bone marrow cells in conditioned medium from CT26 cells, which are genetically modified to secrete high levels of granulocyte-macrophage colony-stimulating factor. This resulted in the generation of high numbers of CD11b(+) Ly6G(+) granulocytic and CD11b(+) Ly6C(+) monocytic MDSC, which closely resemble those found within the tumor but not the spleen of CT26 tumor-bearing mice. Such MDSC potently inhibited T-cell responses in vitro, a process that could be reversed upon blocking of arginase-1 or inducible nitric oxide synthase (iNOS). We confirmed that inhibition of arginase-1 or iNOS in vivo resulted in the stimulation of cytotoxic T-cell responses. A delay in tumor growth was observed upon functional repression of both enzymes. These data confirm the role of MDSC as inhibitors of T-cell-mediated immune responses in CRC. Moreover, MDSC differentiated in vitro from bone marrow cells using conditioned medium of GM-CSF-secreting CT26 cells, represent a valuable platform to study/identify drugs that counteract MDSC activities.


Subject(s)
Colorectal Neoplasms/immunology , Myeloid Cells/immunology , Tumor Escape/immunology , Animals , Cell Differentiation/immunology , Colorectal Neoplasms/pathology , Disease Models, Animal , Female , Flow Cytometry , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , Lymphocyte Activation/immunology , Mice , Mice, Inbred BALB C , T-Lymphocytes/immunology , Transduction, Genetic
3.
World J Gastroenterol ; 20(1): 1-5, 2014 Jan 07.
Article in English | MEDLINE | ID: mdl-24415852

ABSTRACT

The last decade witnessed a significant progress in understanding the biology and immunology of colorectal cancer alongside with the technical innovations in radiotherapy. The stepwise implementation of intensity-modulated and image-guided radiation therapy by means of megavolt computed tomography and helical tomotherapy enabled us to anatomically sculpt dose delivery, reducing treatment related toxicity. In addition, the administration of a simultaneous integrated boost offers excellent local control rates. The novel challenge is the development of treatment strategies for medically inoperable patient and organ preserving approaches. However, distant control remains unsatisfactory and indicates an urgent need for biomarkers that predict the risk of tumor spread. The expected benefit of targeted therapies that exploit the tumor genome alone is so far hindered by high cost techniques and pharmaceuticals, hence hardly justifying rather modest improvements in patient outcomes. On the other hand, the immune landscape of colorectal cancer is now better clarified with regard to the immunosuppressive network that promotes immune escape. Both N2 neutrophils and myeloid-derived suppressor cells (MDSC) emerge as useful clinical biomarkers of poor prognosis, while the growing list of anti-MDSC agents shows promising ability to boost antitumor T-cell immunity in preclinical settings. Therefore, integration of genetic and immune biomarkers is the next logical step towards effective targeted therapies in the context of personalized cancer treatment.


Subject(s)
Antineoplastic Agents/therapeutic use , Immunotherapy/trends , Molecular Targeted Therapy/trends , Precision Medicine/trends , Rectal Neoplasms/therapy , Forecasting , Humans , Radiotherapy/trends , Rectal Neoplasms/drug therapy , Rectal Neoplasms/genetics , Rectal Neoplasms/immunology , Rectal Neoplasms/radiotherapy , Treatment Outcome
4.
Int J Radiat Oncol Biol Phys ; 85(3): 820-7, 2013 Mar 01.
Article in English | MEDLINE | ID: mdl-22975619

ABSTRACT

PURPOSE: To determine whether host hepatocytes may reverse hypoxic radioresistance through nitric oxide (NO)-induced oxygen sparing, in a model relevant to colorectal cancer (CRC) liver metastases. METHODS AND MATERIALS: Hepatocytes and a panel of CRC cells were incubated in a tissue-mimetic coculture system with diffusion-limited oxygenation, and oxygen levels were monitored by an oxygen-sensing fluorescence probe. To activate endogenous NO production, cocultures were exposed to a cytokine mixture, and the expression of inducible nitric oxide synthase was analyzed by reverse transcription-polymerase chain reaction, Western blotting, and NO/nitrite production. The mitochondrial targets of NO were examined by enzymatic activity. To assess hypoxic radioresponse, cocultures were irradiated and reseeded for colonies. RESULTS: Resting hepatocytes consumed 10-40 times more oxygen than mouse CT26 and human DLD-1, HT29, HCT116, and SW480 CRC cells, and thus seemed to be the major effectors of hypoxic conditioning. As a result, hepatocytes caused uniform radioprotection of tumor cells at a 1:1 ratio. Conversely, NO-producing hepatocytes radiosensitized all CRC cell lines more than 1.5-fold, similar to the effect of selective mitochondrial inhibitors. The radiosensitizing effect was associated with a respiratory self-arrest of hepatocytes at the level of aconitase and complex II, which resulted in profound reoxygenation of tumor cells through oxygen sparing. Nitric oxide-producing hepatocytes were at least 10 times more active than NO-producing macrophages to reverse hypoxia-induced radioresistance. CONCLUSIONS: Hepatocytes were the major determinants of the hypoxic microenvironment and radioresponse of CRC cells in our model of metabolic hypoxia. We provide evidence that reoxygenation and radiosensitization of hypoxic CRC cells can be achieved through oxygen sparing induced by endogenous NO production in host hepatocytes.


Subject(s)
Cell Respiration/physiology , Colorectal Neoplasms , Hepatocytes/metabolism , Liver Neoplasms, Experimental/radiotherapy , Mitochondria, Liver/physiology , Nitric Oxide/biosynthesis , Oxygen Consumption/physiology , Radiation Tolerance/physiology , Animals , Cell Hypoxia/physiology , Cell Line, Tumor , Coculture Techniques , Enzyme Induction , HCT116 Cells , HT29 Cells , Hepatocytes/radiation effects , Humans , Liver Neoplasms, Experimental/secondary , Macrophages/metabolism , Mice , Mice, Inbred BALB C , Nitric Oxide Synthase Type II/metabolism , Tumor Microenvironment/physiology
5.
Mol Cancer Ther ; 11(12): 2685-92, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23087257

ABSTRACT

Multiple myeloma is a plasma cell cancer with poor survival, characterized by the clonal expansion of multiple myeloma cells (MMC), primarily in the bone marrow. Novel compounds are currently tested in this disease, but partial or minor patients' responses are observed for most compounds used as a single agent. The design of predictors for drug efficacy could be most useful to better understand basic mechanisms targeted by these drugs and design clinical trials. In the current study, we report the building of a DNA methylation score (DM score) predicting the efficacy of decitabine, an inhibitor of DNA methyltransferase (DNMT), targeting methylation-regulated gene expression. DM score was built by identifying 47 genes regulated by decitabine in human myeloma cell lines and the expression of which in primary MMCs of previously untreated patients is predictive for overall survival. A high DM score predicts patients' poor survival, and, of major interest, high sensitivity of primary MMCs or human myeloma cell lines to decitabine in vitro. Thus, DM score could be useful to design novel treatments with DMNT inhibitor in multiple myeloma and has highlighted 47 genes, the gene products of which could be important for multiple myeloma disease development.


Subject(s)
DNA Methylation/drug effects , DNA Modification Methylases/antagonists & inhibitors , Gene Expression Profiling/methods , Multiple Myeloma/drug therapy , Multiple Myeloma/genetics , Antimetabolites, Antineoplastic/pharmacology , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Cell Line, Tumor , Decitabine , Gene Expression Regulation, Neoplastic/drug effects , Humans , Multiple Myeloma/metabolism , Predictive Value of Tests , Prognosis
SELECTION OF CITATIONS
SEARCH DETAIL
...